DRUG
Bright Minds Biosciences Inc. NASDAQ Listed Mar 22, 2021$79.33
-1.82%
vs $80.80
Mkt Cap $776.4M
52w Low $37.47
48.5% of range
52w High $123.75
50d MA $71.30
200d MA $76.01
P/E (TTM)
—
EV/EBITDA
—
P/B
6.7x
Debt/Equity
0.0x
ROE
—
P/FCF
-62.8x
RSI (14)
59.80
ATR (14)
$3.74
Beta
-0.11
50d MA
$71.30
200d MA
$76.01
Avg Volume
253.2K
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
1500 – 1055 West Georgia Street · New York City, BC V6E 4N7 · CA
Data updated apr 25, 2026 5:48am
· Source: financialmodelingprep.com